The usefulness of pharmacokinetic modulating chemotherapy (UFT plus 5FU) in the treatment of unresectable colorectal carcinomas - PubMed (original) (raw)

Clinical Trial

. 1999 May-Jun;6(3):547-52.

doi: 10.3892/or.6.3.547.

Affiliations

• PMID: 10203589
• DOI: 10.3892/or.6.3.547

Clinical Trial

The usefulness of pharmacokinetic modulating chemotherapy (UFT plus 5FU) in the treatment of unresectable colorectal carcinomas

M Kusunoki et al. Oncol Rep. 1999 May-Jun.

Abstract

This study was performed to improve the prognosis of unresectable (primary non-curative and recurrent) colorectal carcinoma by using pharmacokinetic modulating chemotherapy (PMC), a combination of oral UFT and continuous venous 5FU infusion. The subjects were 120 patients who were prospectively selected for this study. The patients selected PMC or alternative treatment. Fifty-six patients received PMC. The PMC group received 200-400 mg/body/ day UFT orally 5-7 days per week and 600 mg/m2/24 h 5FU infusion once a week. PMC markedly improved the median survival period (26.6 months vs. 9.2 months P<0.000001). This significant improvement as observed in unresectable primary colorectal carcinoma (P=0.0003), recurrent tumors (P<0.00001), local extension (P=0.01), lung metastases (P=0. 03), liver metastases (P=0.0001), and peritoneal seedings (P=0.02). One of 56 patients who received PMC developed grade 4 toxicity. PMC significantly improved the prognosis of unresectable colorectal carcinoma which has a low survival rate. PMC also indicated tolerable compliance and cost effectiveness.

PubMed Disclaimer

Similar articles

• Results of pharmacokinetic modulating chemotherapy in combination with hepatic arterial 5-fluorouracil infusion and oral UFT after resection of hepatic colorectal metastases.
  Kusunoki M, Yanagi H, Noda M, Yoshikawa R, Yamamura T. Kusunoki M, et al. Cancer. 2000 Sep 15;89(6):1228-35. doi: 10.1002/1097-0142(20000915)89:6<1228::aid-cncr6>3.0.co;2-o. Cancer. 2000. PMID: 11002217 Clinical Trial.
• [Usefulness of pharmacokinetic modulating chemotherapy (PMC) for the postoperative adjuvant therapy of colorectal carcinoma: a preliminary report].
  Suzuka I, Izumi S, Onoda Y, Shiota K, Nishihara M, Nakagawa J, Shimizu N. Suzuka I, et al. Gan To Kagaku Ryoho. 1999 Dec;26(14):2183-8. Gan To Kagaku Ryoho. 1999. PMID: 10635302 Clinical Trial. Japanese.
• [Second-line chemotherapy with pharmacokinetic modulating chemotherapy for unresectable colorectal carcinoma recurrences resistant to 5-FU-based chemotherapy].
  Muneoka K, Shirai Y, Wakai T, Yokoyama N, Sakata J, Hatakeyama K. Muneoka K, et al. Gan To Kagaku Ryoho. 2006 Jun;33(6):779-82. doi: 10.2217/14750708.3.6.779. Gan To Kagaku Ryoho. 2006. PMID: 16770096 Japanese.
• UFT and leucovorin: a review of its clinical development and therapeutic potential in the oral treatment of cancer.
  Hoff PM, Pazdur R, Benner SE, Canetta R. Hoff PM, et al. Anticancer Drugs. 1998 Jul;9(6):479-90. Anticancer Drugs. 1998. PMID: 9877235 Review.
• [Chemotherapy for colorectal carcinoma].
  Uetake H, Higuchi T, Enomoto M, Sugihara K. Uetake H, et al. Gan To Kagaku Ryoho. 2003 Nov;30(12):1889-94. Gan To Kagaku Ryoho. 2003. PMID: 14650955 Review. Japanese.

Cited by

• Advances and directions in chemotherapy using implantable port systems for colorectal cancer: a historical review.
  Inoue Y, Kusunoki M. Inoue Y, et al. Surg Today. 2014 Aug;44(8):1406-14. doi: 10.1007/s00595-013-0672-8. Epub 2013 Jul 28. Surg Today. 2014. PMID: 23893159 Free PMC article. Review.
• Current directions in chemotherapy for colorectal cancer.
  Inoue Y, Miki C, Kusunoki M. Inoue Y, et al. J Gastroenterol. 2006 Sep;41(9):821-31. doi: 10.1007/s00535-006-1873-3. J Gastroenterol. 2006. PMID: 17048045 Review. No abstract available.
• Chemotherapy with enteric-coated tegafur/uracil for advanced hepatocellular carcinoma.
  Ishikawa T. Ishikawa T. World J Gastroenterol. 2008 May 14;14(18):2797-801. doi: 10.3748/wjg.14.2797. World J Gastroenterol. 2008. PMID: 18473401 Free PMC article. Review.
• TEGAFIRI is an effective alternative regimen for the management of recurrent or metastatic colorectal cancer.
  Hsu TC. Hsu TC. Oncol Lett. 2015 Mar;9(3):1059-1064. doi: 10.3892/ol.2015.2855. Epub 2015 Jan 7. Oncol Lett. 2015. PMID: 25663857 Free PMC article.
• Schedule-dependent cytotoxicity of 5-fluorouracil and irinotecan in a colon cancer cell line.
  Inoue Y, Miki C, Watanabe H, Hiro J, Toiyama Y, Ojima E, Yanagi H, Kusunoki M. Inoue Y, et al. J Gastroenterol. 2006 Dec;41(12):1149-57. doi: 10.1007/s00535-006-1904-0. Epub 2007 Feb 6. J Gastroenterol. 2006. PMID: 17287894

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ingenta plc
  • Spandidos Publications

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information